Eledon Pharmaceuticals, Inc. (ELDN)
2.30
0.00 (0.00%)
USD |
NASDAQ |
Oct 23, 16:00
2.30
0.00 (0.00%)
After-Hours: 20:00
Eledon Pharmaceuticals Net Income (Quarterly) : -31.63M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -31.63M |
| March 31, 2026 | -39.02M |
| December 31, 2025 | -10.45M |
| September 30, 2025 | -17.46M |
| June 30, 2025 | -11.22M |
| March 31, 2025 | -6.495M |
| December 31, 2024 | -44.62M |
| September 30, 2024 | 54.43M |
| June 30, 2024 | -44.91M |
| March 31, 2024 | -23.63M |
| December 31, 2023 | -85.84M |
| September 30, 2023 | -9.906M |
| June 30, 2023 | -65.76M |
| March 31, 2023 | -10.77M |
| December 31, 2022 | -58.38M |
| September 30, 2022 | -10.47M |
| June 30, 2022 | -9.247M |
| March 31, 2022 | -9.864M |
| December 31, 2021 | -8.806M |
| September 30, 2021 | -9.817M |
| June 30, 2021 | -7.384M |
| March 31, 2021 | -8.499M |
| December 31, 2020 | -5.904M |
| September 30, 2020 | -6.144M |
| June 30, 2020 | -2.586M |
| Date | Value |
|---|---|
| March 31, 2020 | -8.177M |
| December 31, 2019 | -4.144M |
| September 30, 2019 | -2.893M |
| June 30, 2019 | -4.093M |
| March 31, 2019 | -4.881M |
| December 31, 2018 | -4.574M |
| September 30, 2018 | -3.496M |
| June 30, 2018 | -3.189M |
| March 31, 2018 | -2.806M |
| December 31, 2017 | -2.11M |
| September 30, 2017 | -2.97M |
| June 30, 2017 | -5.481M |
| March 31, 2017 | -0.246M |
| December 31, 2016 | -0.223M |
| September 30, 2016 | -0.354M |
| June 30, 2016 | -0.175M |
| March 31, 2016 | -11.43M |
| December 31, 2015 | -11.02M |
| September 30, 2015 | -11.85M |
| June 30, 2015 | -8.957M |
| March 31, 2015 | -13.26M |
| December 31, 2014 | -6.208M |
| September 30, 2014 | -6.39M |
| June 30, 2014 | -5.851M |
| March 31, 2014 | -4.847M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 31.63M |
| EPS Diluted (Quarterly) | -0.2784 |
| Enterprise Value | 136.78M |
| Earnings Yield | -43.06% |
| Normalized Earnings Yield | -39.82 |